Omalizumab in the treatment of various forms of chronic urticaria

Abstract

BACKGROUND: Chronic urticaria is a skin disease characterized by the appearance of itchy weals and/or angioedema for 6 or more weeks. Chronic urticaria is subdivided into chronic spontaneous urticaria, which occurs due to an unknown cause, and chronic inducible urticaria, which occurs as a result of exposure to various physical factors (water, cold, heat, pressure, mechanical irritation), can occur simultaneously or independently of each other. Omalizumab, anti-IgE monoclonal antibody, is approved for the treatment of patients with chronic spontaneous urticaria and is the second choice in cases of resistance to antihistamine treatment. In patients with a combination of chronic spontaneous urticaria and chronic inducible urticaria, the effectiveness of treatment with omalizumab has been little studied.

AIM: compare the effectiveness of omalizumab treatment in patients with chronic spontaneous urticaria and patients with a combination of chronic spontaneous and chronic induced urticaria.

MATERIALS AND METHODS: Under supervision there were 30 patients with chronic spontaneous urticaria and combined chronic spontaneous and inducible urticaria (15 patients in each group). Evaluation of the effectiveness of treatment was carried out according to the results of the questionnaires DLQI (dermatological index of quality of life), CU-Q2oL (questionnaire for quality of life in chronic urticaria), UCT (urticaria control test), UAS (urticaria activity scale), HADS (Hospital Anxiety and Depression Scale) and provocation tests in dynamics before and during treatment.

RESULTS: All patients received omalizumab 300 mg subcutaneously once a month for 6 to 12 months. After the first injection of omalizumab, we noted a decrease in the severity of urticaria, an increase in the level of disease control and quality of life when comparing parameters before and during treatment in more than 90% of patients. Improved performance remained at this level throughout all subsequent months of treatment.

CONCLUSION: Omalizumab is equally effective in patients with an isolated form of chronic spontaneous urticaria and in patients with a combined form of chronic spontaneous and inducible urticaria. The use of omalizumab allows you to control the symptoms of chronic spontaneous and inducible urticaria, even with prolonged use.

Keywords

chronic spontaneous urticaria / chronic inducible urticaria / omalizumab / treatment / effectiveness

References

[1] Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA(2)LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73(7):1393–1414. doi: 10.1111/all.13397

[2] Zuberbier T., Aberer W., Asero R., et al. The EAACI/GA(2)LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria // Allergy. 2018. Vol. 73, N 7. Р. 1393–1414. doi: 10.1111/all.13397

[3] Fricke J, Ávila G, Keller T, et al. Prevalence of chronic urticaria in children and adults across the globe: Systematic review with meta-analysis. Allergy. 2020;75(2):423–432. doi: 10.1111/all.14037

[4] Fricke J., Ávila G., Keller T., et al. Prevalence of chronic urticaria in children and adults across the globe: Systematic review with meta-analysis // Allergy. 2020. Vol. 75, N 2. Р. 423–432. doi: 10.1111/all.14037

[5] Trevisonno J, Balram B, Netchiporouk E, Ben-Shoshan M. Physical urticaria: Review on classification, triggers and management with special focus on prevalence including a meta-analysis. Postgrad Med. 2015;127(6):565–570. doi: 10.1080/00325481.2015.1045817

[6] Trevisonno J., Balram B., Netchiporouk E., Ben-Shoshan M. Physical urticaria: Review on classification, triggers and management with special focus on prevalence including a meta-analysis // Postgrad Med. 2015. Vol. 127, N 6. Р. 565–570. doi: 10.1080/00325481.2015.1045817

[7] Antia C, Baquerizo K, Korman A, et al. Urticaria: A comprehensive review: Epidemiology, diagnosis, and work-up. J Am Acad Dermatol. 2018;79(4):599–614. doi: 10.1016/j.jaad.2018.01.020

[8] Antia C., Baquerizo K., Korman A., et al. Urticaria: A comprehensive review: Epidemiology, diagnosis, and work-up // J Am Acad Dermatol. 2018. Vol. 79, N 4. Р. 599–614. doi: 10.1016/j.jaad.2018.01.020

[9] Sánchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A, et al. Factors linked to disease severity and time to remission in patients with chronic spontaneous urticaria. J Eur Acad Dermatol Venereol. 2017;31(6):964–971. doi: 10.1111/jdv.14221

[10] Sánchez-Borges M., Caballero-Fonseca F., Capriles-Hulett A., et al. Factors linked to disease severity and time to remission in patients with chronic spontaneous urticaria // J Eur Acad Dermatol Venereol. 2017. Vol. 31, N 6. Р. 964–971. doi: 10.1111/jdv.14221

[11] Gonçalo M, Gimenéz-Arnau A, Al-Ahmad M, et al. The global burden of chronic urticaria for the patient and society. Br J Dermatol. 2021;184(2):226–236. doi: 10.1111/bjd.19561

[12] Gonçalo M., Gimenéz-Arnau A., Al-Ahmad M., et al. The global burden of chronic urticaria for the patient and society // Br J Dermatol. 2021. Vol. 184, N 2. Р. 226–236. doi: 10.1111/bjd.19561

[13] Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA(2)LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77(3):734–766. doi: 10.1111/all.15090

[14] Zuberbier T., Abdul Latiff A.H., Abuzakouk M., et al. The international EAACI/GA(2)LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria // Allergy. 2022. Vol. 77, N 3. Р. 734–766. doi: 10.1111/all.15090

[15] Kocatürk E, Can PK, Akbas PE, et al. Management of chronic inducible urticaria according to the guidelines: A prospective controlled study. J Dermatol Sci. 2017;87(1):60–69. doi: 10.1016/j.jdermsci.2017.02.283

[16] Kocatürk E., Can P.K., Akbas P.E., et al. Management of chronic inducible urticaria according to the guidelines: A prospective controlled study // J Dermatol Sci. 2017. Vol. 87, N 1. Р. 60–69. doi: 10.1016/j.jdermsci.2017.02.283

[17] Maurer M, Weller K, Bindslev-Jensen C, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report. Allergy. 2011;66(3):317–330. doi: 10.1111/j.1398-9995.2010.02496.x

[18] Maurer M., Weller K., Bindslev-Jensen C., et al. Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report // Allergy. 2011. Vol. 66, N 3. Р. 317–330. doi: 10.1111/j.1398-9995.2010.02496.x

[19] Maurer M, Rosén K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368(10):924–935. doi: 10.1056/NEJMoa1215372

[20] Maurer M., Rosén K., Hsieh H.J., et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria // N Engl J Med. 2013. Vol. 368, N 10. Р. 924–935. doi: 10.1056/NEJMoa1215372

[21] Kaplan AP, Giménez-Arnau AM, Saini SS. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria. Allergy. 2017;72(4):519–533. doi: 10.1111/all.13083

[22] Kaplan A.P., Giménez-Arnau A.M., Saini S.S. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria // Allergy. 2017. Vol. 72, N 4. Р. 519–533. doi: 10.1111/all.13083

[23] Metz M, Vadasz Z, Kocaturk E, Gimenez-Arnau AM. Omalizumab updosing in chronic spontaneous urticaria: An overview of real-world evidence. Clin Rev Allergy Immunol. 2020;59(1):38–45. doi: 10.1007/s12016-020-08794-6

[24] 12. Metz M., Vadasz Z., Kocaturk E., Gimenez-Arnau A.M. Omalizumab updosing in chronic spontaneous urticaria: An overview of real-world evidence // Clin Rev Allergy Immunol. 2020. Vol. 59, N 1. Р. 38–45. doi: 10.1007/s12016-020-08794-6

[25] Dressler C, Werner RN, Eisert L, et al. Chronic inducible urticaria: A systematic review of treatment options. J Allergy Clin Immunol. 2018;141(5):1726–1734. doi: 10.1016/j.jaci.2018.01.031

[26] Dressler C., Werner R. N., Eisert L., et al. Chronic inducible urticaria: A systematic review of treatment options // J Allergy Clin Immunol. 2018. Vol. 141, N 5. Р. 1726–1734. doi: 10.1016/j.jaci.2018.01.031

[27] Maurer M, Metz M, Brehler R, et al. Omalizumab treatment in patients with chronic inducible urticaria: A systematic review of published evidence. J Allergy Clin Immunol. 2018;141(2):638–649. doi: 10.1016/j.jaci.2017.06.032

[28] Maurer M., Metz M., Brehler R., et al. Omalizumab treatment in patients with chronic inducible urticaria: A systematic review of published evidence // J Allergy Clin Immunol. 2018. Vol. 141, N 2. Р. 638–649. doi: 10.1016/j.jaci.2017.06.032

[29] Dortas Junior S, Azizi G, Valle S. Efficacy of omalizumab in chronic spontaneous urticaria associated with chronic inducible urticaria. Ann Allergy Asthma Immunol. 2020;125(4):486–487. doi: 10.1016/j.anai.2020.06.011

[30] Dortas Junior S., Azizi G., Valle S. Efficacy of omalizumab in chronic spontaneous urticaria associated with chronic inducible urticaria // Ann Allergy Asthma Immunol. 2020. Vol. 125, N 4. Р. 486–487. doi: 10.1016/j.anai.2020.06.011

[31] Dos Santos VR, Bidese LB, de Souza RJ, Maurer M. Effects of omalizumab in a patient with three types of chronic urticaria. Br J Dermatol. 2014;170(2):469–471. doi: 10.1111/bjd.12628

[32] Dos Santos V.R., Bidese L.B., de Souza R.J., Maurer M. Effects of omalizumab in a patient with three types of chronic urticaria // Br J Dermatol. 2014. Vol. 170, N 2. Р. 469–471. doi: 10.1111/bjd.12628

[33] Chen Y, Yu M, Huang X, et al. Omalizumab treatment and outcomes in Chinese patients with chronic spontaneous urticaria, chronic inducible urticaria, or both. World Allergy Organ J. 2021;14(1):100501. doi: 10.1016/j.waojou.2020.100501

[34] Chen Y., Yu M., Huang X., et al. Omalizumab treatment and outcomes in Chinese patients with chronic spontaneous urticaria, chronic inducible urticaria, or both // World Allergy Organ J. 2021. Vol. 14, N 1. Р. 100501. doi: 10.1016/j.waojou.2020.100501

Funding

Аспирант

RIGHTS & PERMISSIONS

Olisova O.Y., Skander D.M.